India’s Hetero receives WHO approval for Nirmacom to treat Covid-19
Pharmaceutical Technology
DECEMBER 27, 2022
Hetero’s Nirmacom combi-pack will contain nirmatrelvir 150 mg (two tablets) and ritonavir 100mg (one tablet). It intends to manufacture the drug at its facility in India. The company has signed a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) to produce and sell nirmatrelvir in LMICs.
Let's personalize your content